The trial met its primary endpoint, as enrichment of transcripts associated with activated dendritic cells and immune recruitment pathways was observed in tumors from patients receiving pepinemab-containing regimens, and immune remodeling was evident by formation of mature lymphoid aggregates resembling tertiary lympho...
A. Ruffin, C. Mallow, B. Olson et al.· Nature Communications· 0 citations
Integrating MetScore with classical–basal identity establishes a two-axis framework that better explains metastatic behavior, prognosis, treatment response, and microenvironmental composition than the conventional one-axis model and provides a clinically testable strategy for transcriptome-guided patient stratification...
Raymond E. Preston, Hong-Yun Huang, Margaret A. Hall et al.· bioRxiv· 0 citations
The emergence of KRAS inhibitors is reshaping the therapeutic landscape of pancreatic ductal adenocarcinoma (PDAC). Yet responses are seldom durable, and relapse is inevitable, highlighting the ongoing need for aggressive therapeutic strategies. PDAC also remains unresponsive to adoptive T cell therapies (ACT), highl...
D. Evans, Megan M. Wyatt, Anna C. Cole et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains refractory to immunotherapies, including adoptive T cell therapy, necessitating evaluation of alternative T cell engineering platforms in immunosuppressive solid tumors. Human CD4+ T cells co-secreting IFN-γ and IL-17A (Th1/17 hybrids) have demonstrated enhanced ant...
Delaney K. Geitgey, Megan M. Wyatt, Maggie J. Phillips et al.· Cancer Research· 0 citations
Bulk deconvolution analysis identifies subtype-specific methylation differences in pancreatic cancer patients and suggests that there are substantial epigenetic changes at the methylation level that contribute to the biological phenotypes of the PDAC subtypes not captured at the transcriptional level.
Erin E. Grundy, Margaret A. Hall, Y. Yoo et al.· Cancer Research· 0 citations
Metastatic cell state is established as an independent and clinically actionable dimension of PDAC biology that complements classical–basal subtype classification and will inform chemotherapy backbone choice in KRAS inhibitor trials, as well as treatment following progression on KRAS inhibitor monotherapy.
Raymond E. Preston, Hong-Yun Huang, Margaret A. Hall et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.